Company profile
BIOMX INC.
AMEX:PHGEBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BX004-A | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05240300 | phase1_2 | withdrawn | 2022-05-01 | 2023-06-01 | BiomX, Inc. | A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis |
| NCT04737876 | phase1 | completed | 2020-10-28 | 2020-12-21 | BiomX, Inc. | A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults |
| NCT05010577 | phase1_2 | completed | 2022-06-21 | 2024-03-10 | BiomX, Inc. | Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection |
| NCT06998043 | phase2 | recruiting | 2025-07-02 | 2026-03-01 | BiomX Ltd | Study With Phage for CF Subjects With Pseudomonas Lung Infection |
FDA applications (0)
No records yet.